Trial Profile
Phase I trial to evaluate the tolerability and pharmacokinetics of NGX-426 in volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2006
Price :
$35
*
At a glance
- Drugs Dasolampanel (Primary)
- Indications Migraine; Neuropathic pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors TorreyPines Therapeutics
- 08 Nov 2006 Status change
- 09 Aug 2006 New trial record.